Literature DB >> 32300194

Benefit from pemigatinib in cholangiocarcinoma.

Diana Romero1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32300194     DOI： 10.1038/s41571-020-0369-z

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Authors:  Ghassan K Abou-Alfa; Teresa Macarulla; Milind M Javle; Robin K Kelley; Sam J Lubner; Jorge Adeva; James M Cleary; Daniel V Catenacci; Mitesh J Borad; John Bridgewater; William P Harris; Adrian G Murphy; Do-Youn Oh; Jonathan Whisenant; Maeve A Lowery; Lipika Goyal; Rachna T Shroff; Anthony B El-Khoueiry; Bin Fan; Bin Wu; Christina X Chamberlain; Liewen Jiang; Camelia Gliser; Shuchi S Pandya; Juan W Valle; Andrew X Zhu
Journal:  Lancet Oncol       Date:  2020-05-13       Impact factor: 41.316
  1 in total
  4 in total

Review 1.  Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.

Authors:  Massimiliano Cadamuro; Alberto Lasagni; Angela Lamarca; Laura Fouassier; Maria Guido; Samantha Sarcognato; Enrico Gringeri; Umberto Cillo; Mario Strazzabosco; Jose Jg Marin; Jesus M Banales; Luca Fabris
Journal:  Expert Opin Investig Drugs       Date:  2021-02-23       Impact factor: 6.206

Review 2.  Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets.

Authors:  Haijun Wang; Jie Yang; Ke Zhang; Jia Liu; Yushan Li; Wei Su; Na Song
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 3.  Fibroblast growth factor receptor fusions in cancer: opportunities and challenges.

Authors:  Lingfeng Chen; Yanmei Zhang; Lina Yin; Binhao Cai; Ping Huang; Xiaokun Li; Guang Liang
Journal:  J Exp Clin Cancer Res       Date:  2021-11-03

Review 4.  Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.

Authors:  Alessandro Rizzo
Journal:  Medicina (Kaunas)       Date:  2021-05-08       Impact factor: 2.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.